The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | Lenalidomide in conjunction with proteasome inhibitors post-stem cell transplant
Thomas Martin
• 14 Sep 2019
Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA discusses the use of lenalidomide as a maintenance-based therapy, and the possibility to use it in conjunction with a proteasome inhibitor such as bortezomib in myeloma patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
